Cure rates in oropharyngeal cancer have gone up, but the quality of life in survivors is often compromised by dysphagia and other side effects.
ESMO 2019 — Controversy — Should therapy be de-escalated in patients with HPV+ oropharyngeal cancer?
(...)
The resource you are trying to access is only available for registered users. To continue please login or create a FREE Univadis® account.
